文献速递湿疹皮炎与荨麻疹银屑病与炎症性皮肤病

NAAA抑制剂ARN077在小鼠过敏性皮炎模型中抑制炎症与瘙痒

The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis.
PubMed 文献 · J Invest Dermatol · 2017-10-18

本研究在小鼠过敏性接触性皮炎模型中评估NAAA抑制剂ARN077的作用。局部应用ARN077以剂量依赖方式减轻DNFB诱导的皮炎表现,增加组织棕榈酰乙醇胺含量并使循环细胞因子和IgE水平正常化,该效应在PPAR-α缺陷小鼠中消失。亚慢性给予ARN077可抑制DNFB诱导的炎症,效果与氯倍他索和地塞米松相当但不引起皮肤萎缩。

要点

  • ARN077局部应用以剂量依赖方式减轻DNFB诱导的小鼠皮炎。
  • ARN077效应依赖PPAR-α,NAAA缺陷小鼠不出现水肿或搔抓行为。
  • 亚慢性ARN077抗炎效果与氯倍他索和地塞米松相当,但不致皮肤萎缩。

核心结论

  • NAAA是开发特应性皮炎及其他炎症性皮肤病有效且安全治疗的有前景靶点。

研究设计与样本

  • 在小鼠过敏性接触性皮炎模型中研究NAAA抑制剂ARN077的性质。
  • 使用DNFB诱导皮炎,并纳入PPAR-α缺陷小鼠和NAAA缺陷小鼠。
  • 比较ARN077与氯倍他索和地塞米松的亚慢性效应。

主要发现

  • 急性局部应用ARN077以剂量依赖方式减轻DNFB诱导皮炎的关键体征。
  • ARN077增加组织棕榈酰乙醇胺含量并使循环细胞因子和免疫球蛋白E水平正常化。
  • PPAR-α缺陷小鼠中未见上述效应。
  • NAAA缺陷小鼠在DNFB激发后未出现水肿或搔抓行为。
  • 亚慢性ARN077在DNFB激发前或后给药均抑制DNFB诱导的炎症,效应呈剂量依赖且与氯倍他索和地塞米松相当。

临床怎么用

  • ARN077局部应用可能作为特应性皮炎的抗炎和止痒治疗选择。
  • NAAA抑制的抗炎效果与糖皮质激素相当但不引起皮肤萎缩。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase highly expressed in macrophages and B lymphocytes, catalyzes the degradation of palmitoylethanolamide. Palmitoylethanolamide is an agonist of PPAR-α and an important regulator of pain and innate immunity. In this study, we investigated the properties of the NAAA inhibitor, ARN077, in a mouse model of allergic contact dermatitis. Acute topical applications of ARN077 attenuated key signs of DNFB-induced dermatitis in a dose-dependent manner. Moreover, ARN077 increased tissue palmitoylethanolamide content and normalized circulating levels of cytokines and immunoglobulin E. No such effect was seen in PPAR-α-deficient mice. Moreover, mice lacking NAAA failed to develop edema or scratching behavior after challenge with DNFB, confirming that this enzyme plays an important role in dermatitis. Consistent with this conclusion, subchronic applications of ARN077 suppressed DNFB-induced inflammation when administered either before or after the DNFB challenge. The effects of subchronic ARN077 were dose dependent and comparable in size to those produced by the steroids clobetasol and dexamethasone. Unlike the latter, however, ARN077 did not cause skin atrophy. The results identify NAAA as a promising target for the development of effective and safe treatments for atopic dermatitis and other inflammatory disorders of the skin.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Sasso O, Summa M, Armirotti A, et al. The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis. J Invest Dermatol. 2017. PMID: 29054595. doi:10.1016/j.jid.2017.07.853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。